Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 3.5 USD 0.86% Market Closed
Market Cap: 193.2m USD

During the last 3 months Voyager Therapeutics Inc insiders have not bought any shares, and sold 300.7k USD worth of shares. The stock price has dropped by 38% over this period (open performance analysis).

The last transaction was made on Apr 2, 2025 by Sandrock Alfred (Chief Executive Officer) , who sold 37.3k USD worth of VYGR shares.

Last Transactions:
Ferguson Toby
Interim Chief Medical Officer
$-34.6k
Sandrock Alfred
Chief Executive Officer
$-37.3k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-14.1k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-16.5k
Sandrock Alfred
Chief Executive Officer
$-49.6k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-24.1k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-30.9k
Fahey Sandell Jacquelyn
Chief Financial Officer
$-19.4k
Sandrock Alfred
Chief Executive Officer
$-74.1k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-15.7k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-6.1k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-36.7k
Fahey Sandell Jacquelyn
Chief Financial Officer
$-34.9k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-13.4k
Sandrock Alfred
Chief Executive Officer
$-119.5k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-29.5k
Sandrock Alfred
Chief Executive Officer
$-97.2k
Pfreundschuh Peter P.
Chief Medical Officer
$-28.1k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-4.6k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-18.2k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-9.1k
Pfreundschuh Peter P.
Chief Medical Officer
$-94.8k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-85.7k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-59.4k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-57.1k
Sandrock Alfred
Chief Executive Officer
$-58.2k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-9.9k
Hesslein Robert W.
General Counsel and Corporate Secretary
$-34.2k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-28.4k
Carter Todd Alfred
Vice President, General Counsel and Secretary
$-17k
Swartz Robin
Vice President, Corporate Communications & Investor Relations
$-126.1k
Neurocrine Biosciences Inc
Chief Executive Officer
$+39m
View All Transactions

During the last 3 months Voyager Therapeutics Inc insiders have not bought any shares, and sold 300.7k USD worth of shares. The stock price has dropped by 38% over this period (open performance analysis).

The last transaction was made on Apr 2, 2025 by Sandrock Alfred (Chief Executive Officer) , who sold 37.3k USD worth of VYGR shares.

Sold
0-3
months
300.7k USD
5
3-6
months
58.5k USD
2
6-9
months
34.9k USD
1
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Voyager Therapeutics Inc
Insider Trading Chart

Voyager Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Voyager Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Voyager Therapeutics Inc
Glance View

Market Cap
191.6m USD
Industry
Biotechnology

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

VYGR Intrinsic Value
4.69 USD
Undervaluation 25%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top